Simultaneous Liver-Kidney Transplant Carries Benefits

Article

Dual transplant may have a protective role against cellular rejection.

Patients who receive simultaneous liver-kidney transplantation may experience long-term benefits compared with patients who receive a kidney transplant alone.

Physicians from the Mayo Clinic examined kidney biopsies from 68 consecutive liver-kidney transplant recipients, 14 with donor specific alloantibodies, and 54 with low or no donor-specific alloantibodies.

The results were then compared to the biopsies of patients who received a kidney transplant alone, including a comparable breakdown of high and low donor specific alloantibodies.

Factors within the study included the overall 5-year patient and graft or transplant survival, acute rejection and chronic kidney damage, and overall measures of kidney function.

The results of a study published in Kidney International found that 5 years after the simultaneous liver-kidney transplant in patients with donor-specific alloantibodies, there was a 7.1% rate of acute rejection compared with 46.4% in patients who had a kidney transplant alone.

“We know that a healthy liver can reduce the levels of circulating donor-specific alloantibodies, which can lead to rejection of a transplanted organ in kidney transplant recipients,” said Timucin Taner, MD, PhD. “The findings from this study indicate that these positive benefits of a healthy liver in simultaneous liver-kidney transplants may be long-standing and that the liver may have a protective role against cellular rejection, as well.”

Additionally, there was no transplant-related kidney injury compared with 53.6% incidence of chronic injury for patients with the kidney transplant alone. The glomerular filtration rate was stable in simultaneous transplant patients, compared with a decline in GFR of 44% of patients with a kidney transplant alone.

“This study is promising, because it demonstrates the power of a well-functioning liver allograft in modulating host immune responses and positively influencing long-term outcomes of the kidney transplant in simultaneous liver-kidney transplant recipients,” Taner said. “More work is needed to better understand how far this benefit extends beyond transplantation, as well as how immunosuppressive therapies impact these outcomes.”

Related Videos
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.